What is MapLight Therapeutics, Inc. 's price / book?

MapLight Therapeutics, Inc. (MPLT) reported price / book of 2.2× in Q1 2026.

What does price / book mean?

Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

MapLight Therapeutics, Inc. MPLT Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

Johnson & JohnsonJNJ

7.3×+2.1×

Neurocrine BiosciencesNBIX

3.9×-0.5×

Acadia PharmaceuticalsACAD

3×-0.6×

AbbVieABBV

261×+221×

LBR

LB Pharmaceuticals Inc Common StockLBRX

1.9×—

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B+100%

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Calculated from MapLight Therapeutics, Inc. ’s reported figures.

market cap/total stockholders equity=2.2×

Based on the most recent quarter.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's price / book?: MapLight Therapeutics, Inc. (MPLT) reported price / book of 2.2× in Q1 2026.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.